Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04530981 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
A Phase 1 study of GIST - Gastrointestinal Stromal Tumor, sponsored by Deciphera Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 3
- Study locations
NCT04530981: Completed Phase 1 study of GIST - Gastrointestinal Stromal Tumor, sponsored by Deciphera Pharmaceuticals.
NCT04530981 is a Phase 1 study of GIST - Gastrointestinal Stromal Tumor that has completed, run by Deciphera Pharmaceuticals. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04530981, a Phase 1 study of GIST - Gastrointestinal Stromal Tumor, has completed, sponsored by Deciphera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 3
- Study locations
Study Summary
Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Substrate
Primary Outcome
Measure the Cmax
Conditions Studied
Interventions
- DRUG Ripretinib
- DRUG Repaglinide
Study Locations (3)
Florida
- Mayo Clinic Florida - Jacksonville
- Sylvester Comprehensive Cancer Center - Miami
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-09-22 |
| Est. Completion | 2024-07-29 |
| Phase | Phase 1 |
What the finished NCT04530981 record still lists
NCT04530981 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).
The record links to 1 condition, with GIST - Gastrointestinal Stromal Tumor appearing as the primary indexed condition, and to 2 interventions - of which Ripretinib is the first listed.
NCT04530981 reports a single indexed study location in Florida, Oregon.
Frequently Asked Questions
What is clinical trial NCT04530981 about?
NCT04530981 is a clinical study titled "A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST". Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Substrate
What is the current status of trial NCT04530981?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2021-09-22. Estimated completion is 2024-07-29.
What conditions does trial NCT04530981 study?
This clinical trial studies the following conditions: GIST - Gastrointestinal Stromal Tumor.
What interventions are being tested in trial NCT04530981?
The interventions under investigation include: Ripretinib (DRUG), Repaglinide (DRUG).
Who is sponsoring clinical trial NCT04530981?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04530981 being conducted?
This trial has 3 study locations across Florida, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04530981's enrollment target sits among peer trials
13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI